Cadonilimab with radiation for recurrent endometrial cancer
Treatments studied
Part of Cancer, Women’s health & pregnancy clinical trials.
This trial tests a combined treatment of the immunotherapy drug cadonilimab plus radiation and chemotherapy for endometrial cancer that has come back or spread to only a few places. The goal is to see if this combination can help control the cancer better.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 80 years old.
- Your cancer has come back (recurred) or spread to a limited number of spots (up to 5) after initial treatment.
- You are able to do most daily activities without help (ECOG 0 or 1).
- You have not had a severe immune reaction to a previous immunotherapy.
- You do not have an active autoimmune disease that requires treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug, cadonilimab (AK104), combined with chemotherapy for women with advanced or recurrent endometrial cancer. The goal is to see if the combination can help shrink or control the cancer.
This trial tests a new immunotherapy drug called cadonilimab combined with radiation therapy for people with locally advanced cervical cancer who cannot receive the usual chemotherapy due to age, kidney problems, heart issues, allergies, or personal choice.
This trial studies whether adding cadonilimab (an immune therapy) to standard radiation can improve treatment for locally advanced cervical cancer. It may help your immune system work better against the cancer while radiation shrinks it.
This trial tests a combination of cadonilimab (an immune-boosting drug) plus chemotherapy for locally advanced cervical cancer that hasn't been treated before. The goal is to see if this combination helps shrink tumors and improve outcomes before surgery.
This trial tests a new drug called cadonilimab for cervical cancer that has come back or spread to other parts of the body. It aims to see how well the drug works in real-world conditions for patients who haven't had many prior treatments.
This trial tests a new immunotherapy drug, cadonilimab, combined with standard chemotherapy followed by chemoradiation for locally advanced cervical cancer. The goal is to see if this combination works better than current treatments.
Hear when a new Endometrial Neoplasms trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.